Literature DB >> 16837864

Progressive prothrombotic state in women with advancing HIV disease.

Alexandra M Levine1, Cheryl Vigen, Jay Gravink, Wendy Mack, C Heather Watts, Howard A Liebman.   

Abstract

BACKGROUND: HIV-infected patients are at increased risk for venous thrombotic events (VTEs). We sought to determine if advancing stages of HIV were associated with coagulation abnormalities that could predispose to VTE.
METHODS: Functional protein S, factor VIII activity, and lupus anticoagulant were assayed in 144 participants of the Women's Interagency HIV Study. Women with conditions associated with VTE (cancer, pregnancy, hormone use, acute infection, cancer, and autoimmune disease) were excluded. Subjects included 34 women with history of clinical AIDS, 11 with immunologic AIDS (CD4 count, <200 cells/dL), 49 with asymptomatic HIV, and 50 HIV-negative comparators.
RESULTS: We found progressive decreases in protein S, when comparing HIV-negative women (median, 76%) to women with asymptomatic HIV (median, 67%), immunologic AIDS (median, 62%), or clinical AIDS (median, 46%; P < 0.0001). Similarly, advancing HIV was associated with stepwise increases in factor VIII, from a median of 116% in HIV-negative women to 149% in those with asymptomatic HIV, 196% in those with immunologic AIDS, and 211% in those with clinical AIDS (P < 0.0001). No subject had lupus anticoagulant.
CONCLUSIONS: Advancing HIV is associated with progressive abnormalities of protein S and factor VIII; both of which are associated with increased risk for VTE, thus providing a biologic mechanism for the increased prevalence of VTE in HIV.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16837864     DOI: 10.1097/01.qai.0000230320.78288.79

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  13 in total

Review 1.  Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era.

Authors:  Nancy F Crum-Cianflone; Jhamillia Weekes; Mary Bavaro
Journal:  AIDS Patient Care STDS       Date:  2008-10       Impact factor: 5.078

2.  Serum concentrations of antiphospholipid and anticardiolipin antibodies are higher in HIV-infected women.

Authors:  Alireza Abdollahi; Afsaneh Morteza
Journal:  Rheumatol Int       Date:  2011-03-30       Impact factor: 2.631

3.  Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV.

Authors:  Laura W Musselwhite; Virginia Sheikh; Thomas D Norton; Adam Rupert; Brian O Porter; Scott R Penzak; Jeff Skinner; JoAnn M Mican; Colleen Hadigan; Irini Sereti
Journal:  AIDS       Date:  2011-03-27       Impact factor: 4.177

4.  Factor VIII concentration is greater in female than male patients with HIV infection.

Authors:  Alireza Abdollahi; Afsaneh Morteza; Omid Khalilzadeh; Ahmad Ahmadzadeh
Journal:  Int J Hematol       Date:  2010-12-15       Impact factor: 2.490

5.  Tobacco smoking and binge alcohol use are associated with incident venous thromboembolism in an HIV cohort.

Authors:  Brandon Luu; Stephanie Ruderman; Robin Nance; Joseph A C Delaney; Jimmy Ma; Andrew Hahn; Susan R Heckbert; Matthew J Budoff; Kristina Crothers; William C Mathews; Katerina Christopolous; Peter W Hunt; Joseph Eron; Richard Moore; Jeanne Keruly; William B Lober; Greer A Burkholder; Amanda Willig; Geetanjali Chander; Mary E McCaul; Karen Cropsey; Conall O'Cleirigh; Inga Peter; Matthew Feinstein; Judith I Tsui; Sara Lindstroem; Michael Saag; Mari M Kitahata; Heidi M Crane; Lydia N Drumright; Bridget M Whitney
Journal:  HIV Med       Date:  2022-03-28       Impact factor: 3.094

6.  Association of hepatitis C with markers of hemostasis in HIV-infected and uninfected women in the women's interagency HIV study (WIHS).

Authors:  Elizabeth M Kiefer; Qiuhu Shi; Donald R Hoover; Robert Kaplan; Russell Tracy; Michael Augenbraun; Chenglong Liu; Marek Nowicki; Phyllis C Tien; Mardge Cohen; Elizabeth T Golub; Kathryn Anastos
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

7.  Association of markers of hemostasis with death in HIV-infected women.

Authors:  Elizabeth Kiefer; Donald R Hoover; Qiuhu Shi; Mark H Kuniholm; Michael Augenbraun; Mardge H Cohen; Elizabeth T Golub; Robert C Kaplan; Chenglong Liu; Marek Nowicki; Phyllis C Tien; Russell P Tracy; Kathryn Anastos
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

8.  Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment.

Authors:  Robert C Kaplan; Alan L Landay; Howard N Hodis; Stephen J Gange; Philip J Norris; Mary Young; Kathryn Anastos; Phyllis C Tien; Xiaonan Xue; Jason Lazar; Christina M Parrinello; Lorie Benning; Russell P Tracy
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-01       Impact factor: 3.731

9.  Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials.

Authors:  Alan R Lifson; Waldo H Belloso; Richard T Davey; Daniel Duprez; Jose M Gatell; Jennifer F Hoy; Eric A Krum; Ray Nelson; Court Pedersen; George Perez; Richard W Price; Ronald J Prineas; Frank S Rhame; James H Sampson; John Worley
Journal:  HIV Clin Trials       Date:  2010 Jul-Aug

10.  Impact of Obliterative Portal Venopathy Associated With Human Immunodeficiency Virus.

Authors:  Clémence Hollande; Vincent Mallet; Stéphane Darbeda; Anaïs Vallet-Pichard; Hélène Fontaine; Virginie Verkarre; Philippe Sogni; Benoit Terris; Hervé Gouya; Stanislas Pol
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.